Zealand Pharma Presents New Preclinical Data on its GLP-1-Gastrin Dual Agonist, Which Shows Potential as a Novel Approach for the Treatment and/or Prevention of Type 2 Diabetes

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Copenhagen, 26 September 2013 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that new preclinical data on ZP3022, a novel peptide receptor agonist from the company’s GLP-1-gastrin dual agonist program, is presented during a poster session today entitled “Effects of a novel GLP-1-gastrin dual agonist, ZP3022, on beta cell proliferation, apoptosis and functional capacity” at the 49th European Association for the Study of Diabetes (EASD) in Barcelona, Spain.

Help employers find you! Check out all the jobs and post your resume.

Back to news